Abstract
Introduction: Kaposi’s sarcoma (KS) is a multicentric angiomatous neoplasm of lymphatic endothelium-derived cells that leads to angioproliferative diseases and affects the skin and internal organs. Currently, the main treatment options include radiotherapy, chemotherapy and targeted treatment. However, due to the low incidence rate and high malignancy, prognosis remains dismal and thus novel strategies are warranted. Methods: We treated 3 cases of KS with sirolimus, and evaluated the effectiveness and related side effects. Two were not suitable for chemotherapy, andone refused chemotherapy. Results: In this study, three patients all achieved symptom relief within three days. One patient died of pulmonary infection, and the overall survival time was 12.0 months. The other two patients had not reached disease progression, and the progression free survival time (PFS) of one patient was more than 18 months. The main adverse reaction was grade 1-2 oral mucositis, which was well controlled and well tolerated. Conclusion: This study shows the long-term remission of lesions and satisfactory safety of oral sirolimus in KS patients who are unsuitable for chemotherapy or refuse chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
